Last reviewed · How we verify

DEXMEDETOMIDINE

FDA-approved approved Small molecule Quality 5/100

DEXMEDETOMIDINE is a drug. It is currently FDA-approved (first approved 1999).

At a glance

Generic nameDEXMEDETOMIDINE
ModalitySmall molecule
PhaseFDA-approved
First approval1999

Approved indications

No approved indications tracked.

Common side effects

Serious adverse events

Key clinical trials

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

SourceUsed for
FDA labelMechanism, indications, dosing, boxed warnings, drug interactions
ClinicalTrials.govTrial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

Frequently asked questions about DEXMEDETOMIDINE

What is DEXMEDETOMIDINE?

DEXMEDETOMIDINE is a Small molecule drug.

When was DEXMEDETOMIDINE approved?

DEXMEDETOMIDINE was first approved on 1999.

What development phase is DEXMEDETOMIDINE in?

DEXMEDETOMIDINE is FDA-approved (marketed).

What are the side effects of DEXMEDETOMIDINE?

Common side effects of DEXMEDETOMIDINE include Hypotension, Bradycardia, Hypertension, Nausea, Dry Mouth, Vomiting. Serious adverse events: Hypotension Requiring Intervention, Bradycardia Requiring Intervention, Ventricular Tachycardia, Pulmonary Edema.

Related

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing